A Prospective Cohort Study on Warfarin Personalized Medication
- Conditions
- Warfarin Sodium Causing Adverse Effects in Therapeutic Use
- Registration Number
- NCT06428110
- Lead Sponsor
- Haobin Li
- Brief Summary
Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 272
-
Patients aged 65 years and older, taking warfarin, with or without premature vascular aging, regardless of gender.
-
Patients who have not concurrently or intermittently used anticoagulant drugs, including antiplatelet drugs, heparin, low molecular weight heparin, and non-vitamin K-dependent oral anticoagulants, such as dabigatran and apixaban.
- Signing an informed consent form before blood sample collection.
-
-
Patients who are allergic to warfarin or lactose.
-
Patients who are receiving immunosuppressive agents or low molecular weight heparin anticoagulants.
-
Patients with bleeding tendencies, blood disorders with platelet counts > 400 × 10^9 /L or < 100 × 10^9 /L, hemoglobin > 169 or < 100 g/L.
-
History of peptic ulcer disease.
-
Malignant tumors, severe multi-organ dysfunction or failure such as heart, liver, and kidney.
- Neurological disorders such as epilepsy.
-
-
-
-
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Numbers of patients with bleeding events 1 year during the follow-up Numbers of patients with bleeding events during warfarin treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Fifth People's Hospital of Shanghai
🇨🇳Shanghai, Shanghai, China